BioNote, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
BioNote, Inc. - overview
Established
2003
Location
Hwaseong, Gyeonggi-do, South Korea
Primary Industry
Pharmaceuticals
About
Based in Hwaseong-si, South Korea, and founded in 2003, BioNote, Inc. is a pharmaceutical and medical device company that specializes in the production and R&D of veterinary diagnostic pharmaceuticals and diagnostic products for animals and human diseases. The company was first founded as Anigen Inc and changed to its current name in 2015. In 2006, the company acquired a patent for 'Manufacturing Canine parvovirus antibody diagnostic kit with rapid immune chromatography' In 2009, BioNote, Inc.
's veterinary medicine manufacturing permits passed the USDA review. In 2020, the company developed 'NowCheck COVID-19 Ag/Ab Test' kit which can detect SARS-CoV-2 antigens present in the human nasopharynx cavity. The current CEO of the company is Byung-ki Cho. BioNote, Inc.
's main products include 'Vcheck' devices (fluorescent Immunoassay analyzer specialized for animal clinics), 'Vcheck Quantitative Test Reagents' (reagents that can check the quantified result values for Vcheck devices), 'AIV Ab ELISA' (Avian Influenza Virus Antibody detector), 'NowCheck' (chromatographic immunoassay for the detection of specific SARS-CoV-2 antigens), and etc. The company has several R&D centers in South Korea that develop antigens, antibodies, detection kits, reagents, and other pharmaceuticals for disease detection.
Current Investors
InterVest, Korea Investment & Securities, Shinhan Securities
Primary Industry
Pharmaceuticals
Sub Industries
Biotechnology, Diagnostic Equipment, Pharmaceuticals
Website
www.bionote.co.kr
Verticals
HealthTech, Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
BioNote, Inc. - financials
| Fiscal Year Ended | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 20,081,261,769 | 24,899,081,914 | 33,129,194,608 | 34,391,322,094 | 40,047,496,797 | 631,504,544,796 | 622,355,164,435 | 479,657,089,813 | - | - | - |
| % Revenue Growth (YoY) | - | 24.0% | 33.1% | 3.8% | 16.4% | 1476.9% | (1.4%) | (22.9%) | - | - | - |
| EBITDA (USD) | 5,220,904,180 | 4,918,376,841 | 8,415,289,475 | 7,838,005,749 | 11,229,716,797 | 559,918,323,819 | 474,195,960,089 | 301,860,815,762 | - | - | - |
| Operating Income (USD) | 4,676,329,726 | 4,143,322,064 | 7,323,747,825 | 6,567,002,493 | 9,861,571,839 | 558,030,969,819 | 470,089,786,089 | 295,409,547,762 | - | - | - |
| Operating Margin | 23.3% | 16.6% | 22.1% | 19.1% | 24.6% | 88.4% | 75.5% | 61.6% | - | - | - |
| % EBITDA Margin | 26.0% | 19.8% | 25.4% | 22.8% | 28.0% | 88.7% | 76.2% | 62.9% | - | - | - |
| NET Income (USD) | 4,529,012,655 | 4,433,665,877 | 6,284,013,994 | 5,561,057,852 | 8,541,046,558 | 528,228,844,808 | 671,556,498,817 | 307,797,756,625 | - | - | - |
| % Net Margin | 22.6% | 17.8% | 19.0% | 16.2% | 21.3% | 83.6% | 107.9% | 64.2% | - | - | - |
BioNote, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | EuBiologics Co. Ltd. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.